/AKBA
AKBA Stock - Akebia Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.66-0.60%
$0.01 (-0.60%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+291.6%upside
Target: $6.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AKBA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.64 – $1.68
TARGET (TP)$6.50
STOP LOSS$1.53
RISK/REWARD1:37.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.31
52W High$4.08
52W Low$1.45
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $160.18M | $194.62M | $292.48M | $211.65M | $294.64M |
| Gross Profit | $97.00M | $120.47M | $269.99M | $130.16M | $230.68M |
| Gross Margin | 60.6% | 61.9% | 92.3% | 61.5% | 78.3% |
| Operating Income | $-50,472,000 | $-46,256,000 | $-80,779,000 | $-264,502,000 | $-377,826,000 |
| Net Income | $-69,410,000 | $-51,925,000 | $-94,226,000 | $-282,024,000 | $-384,841,000 |
| Net Margin | -43.3% | -26.7% | -32.2% | -133.3% | -130.6% |
| EPS | $-0.33 | $-0.28 | $-0.58 | $-1.48 | $-2.53 |
Company Overview
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↑ 228.8% Upside
Now
$4
Low
$5
Average
$8
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 4th 2025 | H.C. Wainwright | Resumed | Buy | $8 |
| April 28th 2025 | Leerink Partners | Initiation | Outperform | $7 |
| April 1st 2025 | Jefferies | Initiation | Buy | $6 |
| November 29th 2023 | BTIG Research | Resumed | Buy | $4 |
| August 28th 2023 | H.C. Wainwright | Upgrade | Buy | $3.75 |
| May 31st 2023 | Piper Sandler | Upgrade | Overweight | $4← $2 |
Earnings History & Surprises
AKBABeat Rate
44%
Last 18 quarters
Avg Surprise
+3.4%
EPS vs Estimate
Beats / Misses
8/9
1 met exactly
Latest EPS
$0.00
Q4 2025
EPS Surprise History
Q1 24
+100.0%
$0.00vs$0.00
Q2 24
0.0%
$-0.09vs$-0.09
Q3 24
+33.3%
$-0.04vs$-0.06
Q4 24
-100.0%
$-0.10vs$-0.05
Q1 25
-100.0%
$-0.10vs$-0.05
Q2 25
+200.0%
$0.03vs$-0.03
Q3 25
+104.6%
$0.00vs$-0.02
Q4 25
-86.9%
$0.00vs$0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $0.02 | — | — | — |
Q4 2025 | Nov 10, 2025 | $0.01 | $0.00 | -86.9% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.02 | $0.00 | +104.6% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.03 | $0.03 | +200.0% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $-0.05 | $-0.10 | -100.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.05 | $-0.10 | -100.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.06 | $-0.04 | +33.3% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.09 | $-0.09 | 0.0% | = MET |
Q1 2024 | Mar 14, 2024 | $0.00 | $0.00 | +100.0% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q3 2023 | Aug 25, 2023 | $-0.03 | $-0.06 | -140.0% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-0.15 | $-0.14 | +6.7% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-0.14 | $-0.04 | +71.4% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.15 | $-0.28 | -86.7% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.31 | $0.23 | +174.2% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.27 | $-0.35 | -29.6% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-0.33 | $-0.40 | -21.2% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.32 | $-0.34 | -6.3% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.30 | $-0.51 | -70.0% | ✗ MISS |
Latest News
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $5 Price Target
📈 PositiveBenzinga•Dec 2, 2025, 03:45 PM
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target
📈 PositiveBenzinga•Dec 2, 2025, 12:12 PM
Q32 Bio shares are trading higher after the company sold its Phase 2 complement inhibitor ADX-097 to Akebia for $12 million upfront and potential milestone and royalty payments up to $592 million.
📈 PositiveBenzinga•Dec 1, 2025, 12:54 PM•Also:
Akebia Therapeutics Evaluates Praliciguat In FSGS Clinical Trial, With Plans To Expand Into Other Rare Podocytopathies
📈 PositiveBenzinga•Dec 1, 2025, 12:10 PM
Akebia Therapeutics Establishes Rare Kidney Disease Pipeline With AKB-097 Acquisition From Q32 Bio And Praliciguat Candidate
📈 PositiveBenzinga•Dec 1, 2025, 12:09 PM•Also:
Akebia Therapeutics Established Its Rare Kidney Disease Pipeline Comprising Two Core Product Candidates- ADX-097 (Now Referred To As AKB-097) And Praliciguat, Both Trials Planned To Start Treating Subjects In 2026
📈 PositiveBenzinga•Dec 1, 2025, 12:08 PM
Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics For $12M Upfront Payment; Co. Eligible To receive Up To $592M In Milestones As Well As Royalties
📈 PositiveBenzinga•Dec 1, 2025, 12:08 PM•Also:
Akebia Therapeutics shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 10, 2025, 02:26 PM
Akebia Therapeutics Q3 Sales $58.766M Beat $58.235M Estimate
📈 PositiveBenzinga•Nov 10, 2025, 12:04 PM
Akebia Therapeutics Presents Data At ASN Kidney Week Says Vadadustat Shows Statistically Significant Reduction In Death And Hospitalization In Dialysis Patients
📈 PositiveBenzinga•Nov 6, 2025, 11:35 PM
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $6
➖ NeutralBenzinga•Oct 30, 2025, 11:51 AM
BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $5
📈 PositiveBenzinga•Oct 29, 2025, 05:49 PM
Akebia Therapeutics shares are trading lower after the company said it will not initiate the VALOR trial following a lack of alignment with the FDA on trial design for Vafseo in CKD non-dialysis patients.
📉 NegativeBenzinga•Oct 29, 2025, 10:40 AM
Akebia plummets as it abandons Vafseo for non-dialysis patients
📉 NegativeSeeking Alpha•Oct 28, 2025, 09:45 PM
Akebia Therapeutics shares are trading lower after the company said it will not initiate the VALOR trial following a lack of alignment with the FDA on trial design for Vafseo in CKD non-dialysis patients.
📉 NegativeBenzinga•Oct 28, 2025, 08:35 PM
Akebia Therapeutics Says FDA Has Not Come To Alignment On Path Forward For Design Of VALOR Clinical Trial For Use Of Vafseo In Non-Dialysis Patients
📉 NegativeBenzinga•Oct 28, 2025, 08:34 PM
Akebia Therapeutics And Innovative Renal Care Announce Vafseo Availability In IRC Dialysis Clinics
📈 PositiveBenzinga•Aug 21, 2025, 12:10 PM
Frequently Asked Questions about AKBA
What is AKBA's current stock price?
Akebia Therapeutics, Inc. (AKBA) is currently trading at $1.66 per share. The stock has moved -0.60% today.
What is the analyst price target for AKBA?
The average analyst price target for AKBA is $6.50, based on 1 analyst.
What sector is Akebia Therapeutics, Inc. in?
Akebia Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AKBA's market cap?
Akebia Therapeutics, Inc. has a market capitalization of $0.44 billion, making it a small-cap company.
Does AKBA pay dividends?
No, Akebia Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCMPX
Compass Therapeutics, Inc.
$4.99
Mkt Cap: $0.7B
CRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
PRTA
Prothena Corporation plc
$9.21
Mkt Cap: $0.5B
RIGL
Rigel Pharmaceuticals, Inc.
$41.59
Mkt Cap: $0.7B
VTYX
Ventyx Biosciences, Inc.
$8.74
Mkt Cap: $0.6B
ZVRA
Zevra Therapeutics, Inc.
$8.31
Mkt Cap: $0.5B
Explore stocks similar to AKBA for comparison